With its new factory, due to open in early 2025, ARaymondlife is opening a new chapter in its development.
![BIM-GSE-ARAYMOND-Ext_DR.jpg BIM-GSE-ARAYMOND-Ext_DR.jpg](https://www.medicalplasticsnews.com/downloads/10115/download/BIM-GSE-ARAYMOND-Ext_DR.jpg?cb=4c969e3f674a8d2ecf1e5dd3bfb6928d&w={width}&h={height})
Araymond
Developed by the ARaymondlife design office, RayDyLyo was launched in 2012 as an alternative to the aluminium cap. At the time, it responded to regulatory developments in aseptic filling, concerning controlled atmosphere zones for the manufacture of sterile drugs, to limit the risks of microbial and particulate contamination.
Since then, due to a number of international partners, ARaymondlife has expanded the use of its closures on a large number of filling machines, and offers a range of packaging options.
"Unlike our competitors, we retain ownership of the concepts we develop, which are based on the ARaymond Group's expertise in injection, assembly and fluid connections. The strength and stability of our group (soon to celebrate its 160th anniversary), as well as its capacity for innovation, are placed at the service of our customers' projects" explains Patrick Delorme, chairman of ARaymondlife.
To support its ambitions and the healthcare activity, the ARaymond group is investing 66 million euros (building and equipment) in a new production site, based in northern Isère.
With a surface area almost four times larger than its predecessor (14,000 m² as opposed to 3,700 m² ), this facility will increase production capacity, for RayDyLyo, to 250 million parts/annum, compared with 15 million today. The 100 employees will move to the new site in early 2025. Eventually, the workforce should reach 350.